Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise Researchers at Washington University School of Medicine in St. Louis have ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.

The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...

Scientists believe they have found a major link between Alzheimer's disease and a dieting hack, which is followed by millions ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.